farglitazar has been researched along with gw 7845 in 5 studies
| Studies (farglitazar) | Trials (farglitazar) | Recent Studies (post-2010) (farglitazar) | Studies (gw 7845) | Trials (gw 7845) | Recent Studies (post-2010) (gw 7845) |
|---|---|---|---|---|---|
| 35 | 3 | 5 | 35 | 0 | 6 |
| Protein | Taxonomy | farglitazar (IC50) | gw 7845 (IC50) |
|---|---|---|---|
| Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | 10 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blanchard, SG; Brackeen, MF; Brown, KK; Cobb, JE; Collins, JL; Harrington, WW; Hashim, MA; Henke, BR; Hull-Ryde, EA; Kaldor, I; Kliewer, SA; Lake, DH; Leesnitzer, LM; Lehmann, JM; Lenhard, JM; Miller, JF; Mook, RA; Noble, SA; Oliver, W; Orband-Miller, LA; Parks, DJ; Plunket, KD; Szewczyk, JR; Willson, TM | 1 |
| Blanchard, SG; Boswell, EG; Brown, KK; Charifson, PS; Cobb, JE; Collins, JL; Cooper, JP; Dezube, M; Henke, BR; Hull-Ryde, EA; Lake, DH; Lenhard, JM; Oliver, W; Oplinger, J; Parks, DJ; Pentti, M; Plunket, KD; Tong, WQ | 1 |
| Brown, PJ; Henke, BR; Sternbach, DD; Willson, TM | 1 |
| Ayscue, AH; Henke, BR; Lambert, MH; Leesnitzer, LM; Liu, KG; Oliver, WR; Plunket, KD; Sternbach, DD; Willson, TM; Xu, HE | 1 |
| Bonev, AD; Eckman, DM; Gomez, MF; Heppner, TJ; Nelson, MT; Petkov, GV | 1 |
1 review(s) available for farglitazar and gw 7845
| Article | Year |
|---|---|
The PPARs: from orphan receptors to drug discovery.
Topics: Animals; Diabetes Mellitus; Drug Design; Humans; Hyperlipidemias; Hypertension; Inflammation; Ligands; Models, Molecular; Neoplasms; Nuclear Proteins; Obesity; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2000 |
4 other study(ies) available for farglitazar and gw 7845
| Article | Year |
|---|---|
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
Topics: Administration, Oral; Aminopyridines; Animals; Blood Glucose; Cell Line; Diabetes Mellitus, Experimental; DNA-Binding Proteins; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Ligands; Lipids; Male; Mice; Oxazoles; Propionates; Radioligand Assay; Rats; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; Stereoisomerism; Structure-Activity Relationship; Transcription Factors; Transfection; Tyrosine | 1998 |
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent.
Topics: Administration, Oral; Animals; Benzoates; Blood Glucose; Cell Line; Diabetes Mellitus, Experimental; DNA-Binding Proteins; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Ligands; Lipids; Male; Mice; ortho-Aminobenzoates; Oxazoles; Radioligand Assay; Rats; Receptors, Cytoplasmic and Nuclear; Solubility; Structure-Activity Relationship; Transcription Factors; Tyrosine | 1998 |
Synthesis and biological activity of L-tyrosine-based PPARgamma agonists with reduced molecular weight.
Topics: Animals; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Male; Molecular Weight; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Transcription Factors; Tyrosine | 2001 |
Novel PPARgamma agonists GI 262570, GW 7845, GW 1929, and pioglitazone decrease calcium channel function and myogenic tone in rat mesenteric arteries.
Topics: Algorithms; Animals; Barium; Benzophenones; Blood Pressure; Calcium Channels; Electrophysiology; Female; Hypoglycemic Agents; In Vitro Techniques; Membrane Potentials; Mesenteric Arteries; Muscle Cells; Muscle Tonus; Muscle, Smooth, Vascular; Oxazoles; Patch-Clamp Techniques; Pioglitazone; PPAR gamma; Rats; Rats, Sprague-Dawley; Thiazolidinediones; Tyrosine; Vasodilation | 2005 |